Cargando…

Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report

Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shaoxing, Sun, Wenjie, Xiang, Qingming, Yang, Chunxu, Chen, Min, Mei, Zijie, Yang, Hui, Zeng, Zihang, Cao, Hong, Tian, Yueli, Zhang, Gong, Qiu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670358/
https://www.ncbi.nlm.nih.gov/pubmed/34338238
http://dx.doi.org/10.1097/CAD.0000000000001178
_version_ 1784614963998883840
author Sun, Shaoxing
Sun, Wenjie
Xiang, Qingming
Yang, Chunxu
Chen, Min
Mei, Zijie
Yang, Hui
Zeng, Zihang
Cao, Hong
Tian, Yueli
Zhang, Gong
Qiu, Hui
author_facet Sun, Shaoxing
Sun, Wenjie
Xiang, Qingming
Yang, Chunxu
Chen, Min
Mei, Zijie
Yang, Hui
Zeng, Zihang
Cao, Hong
Tian, Yueli
Zhang, Gong
Qiu, Hui
author_sort Sun, Shaoxing
collection PubMed
description Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in approximately all published clinical trials. Surprisingly patients with complete response were also noticed as an anecdote. Proper indicators of treatment response were urgently required. Programmed death- ligand 1 expression levels in the tumor tissues provide relatively limited discrimination. Tumor mutation burden (TMB) serves as a more reliable parameter. Here we presented an ovarian cancer case with multiple gene mutations and high TMB, who benefited from a short-term treatment of pembrolizumab and experienced a long-lasting complete response of 2 years till now. The patient was irradiated in the pelvic before pembrolizumab. Our study demonstrated that ICIs might provide survival benefits for ovarian cancer with high TMB and that pelvic radiation might have synergistical effects with immunotherapy.
format Online
Article
Text
id pubmed-8670358
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-86703582021-12-15 Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report Sun, Shaoxing Sun, Wenjie Xiang, Qingming Yang, Chunxu Chen, Min Mei, Zijie Yang, Hui Zeng, Zihang Cao, Hong Tian, Yueli Zhang, Gong Qiu, Hui Anticancer Drugs Case Reports Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in approximately all published clinical trials. Surprisingly patients with complete response were also noticed as an anecdote. Proper indicators of treatment response were urgently required. Programmed death- ligand 1 expression levels in the tumor tissues provide relatively limited discrimination. Tumor mutation burden (TMB) serves as a more reliable parameter. Here we presented an ovarian cancer case with multiple gene mutations and high TMB, who benefited from a short-term treatment of pembrolizumab and experienced a long-lasting complete response of 2 years till now. The patient was irradiated in the pelvic before pembrolizumab. Our study demonstrated that ICIs might provide survival benefits for ovarian cancer with high TMB and that pelvic radiation might have synergistical effects with immunotherapy. Lippincott Williams & Wilkins 2021-07-30 2022-01 /pmc/articles/PMC8670358/ /pubmed/34338238 http://dx.doi.org/10.1097/CAD.0000000000001178 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Sun, Shaoxing
Sun, Wenjie
Xiang, Qingming
Yang, Chunxu
Chen, Min
Mei, Zijie
Yang, Hui
Zeng, Zihang
Cao, Hong
Tian, Yueli
Zhang, Gong
Qiu, Hui
Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title_full Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title_fullStr Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title_full_unstemmed Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title_short Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
title_sort persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670358/
https://www.ncbi.nlm.nih.gov/pubmed/34338238
http://dx.doi.org/10.1097/CAD.0000000000001178
work_keys_str_mv AT sunshaoxing persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT sunwenjie persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT xiangqingming persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT yangchunxu persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT chenmin persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT meizijie persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT yanghui persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT zengzihang persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT caohong persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT tianyueli persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT zhanggong persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport
AT qiuhui persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport